Cargando…

Renal Soluble Guanylate Cyclase Is Downregulated in Sunitinib‐Induced Hypertension

BACKGROUND: The tyrosine kinase inhibitor sunitinib causes hypertension associated with reduced nitric oxide (NO) availability, elevated renal vascular resistance, and decreased fractional sodium excretion. We tested whether (1) nitrate supplementation mitigates sunitinib‐induced hypertension and NO...

Descripción completa

Detalles Bibliográficos
Autores principales: Witte, Jeannine, Mühlbauer, Melanie, Braun, Diana, Steinbach, Antje, Golchert, Janine, Rettig, Rainer, Grisk, Olaf
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6222942/
https://www.ncbi.nlm.nih.gov/pubmed/30371202
http://dx.doi.org/10.1161/JAHA.118.009557
_version_ 1783369324870762496
author Witte, Jeannine
Mühlbauer, Melanie
Braun, Diana
Steinbach, Antje
Golchert, Janine
Rettig, Rainer
Grisk, Olaf
author_facet Witte, Jeannine
Mühlbauer, Melanie
Braun, Diana
Steinbach, Antje
Golchert, Janine
Rettig, Rainer
Grisk, Olaf
author_sort Witte, Jeannine
collection PubMed
description BACKGROUND: The tyrosine kinase inhibitor sunitinib causes hypertension associated with reduced nitric oxide (NO) availability, elevated renal vascular resistance, and decreased fractional sodium excretion. We tested whether (1) nitrate supplementation mitigates sunitinib‐induced hypertension and NO contributes less to renal vascular resistance as well as fractional sodium excretion regulation in sunitinib‐treated rats than in controls; and (2) renal soluble guanylate cyclase (sGC) is downregulated and sGC activation lowers arterial pressure in rats with sunitinib‐induced hypertension. METHODS AND RESULTS: Arterial pressure responses to nitrate supplementation and the effects of systemic and intrarenal NO synthase (NOS) inhibition on renal hemodynamics and fractional sodium excretion were assessed in sunitinib‐treated rats and controls. Renal NOS and sGC mRNA as well as protein abundances were determined by quantitative polymerase chain reaction and Western blot. The effect of the sGC activator cinaciguat on arterial pressure was investigated in sunitinib‐treated rats. Nitrate supplementation did not mitigate sunitinib‐induced hypertension. Endothelium‐dependent reductions in renal vascular resistance were similar in control and sunitinib‐treated animals without and with systemic NOS inhibition. Selective intrarenal NOS inhibition lowered renal medullary blood flow in control but not in sunitinib‐treated rats without significant effects on fractional sodium excretion. Renal cortical sGC mRNA and sGC α(1)‐subunit protein abundance were less in sunitinib‐treated rats than in controls, and cinaciguat effectively lowered arterial pressure by 15‐20 mm Hg in sunitinib‐treated rats. CONCLUSIONS: Renal cortical sGC is downregulated in the presence of intact endothelium‐dependent renal vascular resistance regulation in developing sunitinib‐induced hypertension. This suggests that sGC downregulation occurs outside the renal vasculature, increases renal sodium retention, and contributes to nitrate resistance of sunitinib‐induced hypertension.
format Online
Article
Text
id pubmed-6222942
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-62229422018-11-19 Renal Soluble Guanylate Cyclase Is Downregulated in Sunitinib‐Induced Hypertension Witte, Jeannine Mühlbauer, Melanie Braun, Diana Steinbach, Antje Golchert, Janine Rettig, Rainer Grisk, Olaf J Am Heart Assoc Original Research BACKGROUND: The tyrosine kinase inhibitor sunitinib causes hypertension associated with reduced nitric oxide (NO) availability, elevated renal vascular resistance, and decreased fractional sodium excretion. We tested whether (1) nitrate supplementation mitigates sunitinib‐induced hypertension and NO contributes less to renal vascular resistance as well as fractional sodium excretion regulation in sunitinib‐treated rats than in controls; and (2) renal soluble guanylate cyclase (sGC) is downregulated and sGC activation lowers arterial pressure in rats with sunitinib‐induced hypertension. METHODS AND RESULTS: Arterial pressure responses to nitrate supplementation and the effects of systemic and intrarenal NO synthase (NOS) inhibition on renal hemodynamics and fractional sodium excretion were assessed in sunitinib‐treated rats and controls. Renal NOS and sGC mRNA as well as protein abundances were determined by quantitative polymerase chain reaction and Western blot. The effect of the sGC activator cinaciguat on arterial pressure was investigated in sunitinib‐treated rats. Nitrate supplementation did not mitigate sunitinib‐induced hypertension. Endothelium‐dependent reductions in renal vascular resistance were similar in control and sunitinib‐treated animals without and with systemic NOS inhibition. Selective intrarenal NOS inhibition lowered renal medullary blood flow in control but not in sunitinib‐treated rats without significant effects on fractional sodium excretion. Renal cortical sGC mRNA and sGC α(1)‐subunit protein abundance were less in sunitinib‐treated rats than in controls, and cinaciguat effectively lowered arterial pressure by 15‐20 mm Hg in sunitinib‐treated rats. CONCLUSIONS: Renal cortical sGC is downregulated in the presence of intact endothelium‐dependent renal vascular resistance regulation in developing sunitinib‐induced hypertension. This suggests that sGC downregulation occurs outside the renal vasculature, increases renal sodium retention, and contributes to nitrate resistance of sunitinib‐induced hypertension. John Wiley and Sons Inc. 2018-09-07 /pmc/articles/PMC6222942/ /pubmed/30371202 http://dx.doi.org/10.1161/JAHA.118.009557 Text en © 2018 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Original Research
Witte, Jeannine
Mühlbauer, Melanie
Braun, Diana
Steinbach, Antje
Golchert, Janine
Rettig, Rainer
Grisk, Olaf
Renal Soluble Guanylate Cyclase Is Downregulated in Sunitinib‐Induced Hypertension
title Renal Soluble Guanylate Cyclase Is Downregulated in Sunitinib‐Induced Hypertension
title_full Renal Soluble Guanylate Cyclase Is Downregulated in Sunitinib‐Induced Hypertension
title_fullStr Renal Soluble Guanylate Cyclase Is Downregulated in Sunitinib‐Induced Hypertension
title_full_unstemmed Renal Soluble Guanylate Cyclase Is Downregulated in Sunitinib‐Induced Hypertension
title_short Renal Soluble Guanylate Cyclase Is Downregulated in Sunitinib‐Induced Hypertension
title_sort renal soluble guanylate cyclase is downregulated in sunitinib‐induced hypertension
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6222942/
https://www.ncbi.nlm.nih.gov/pubmed/30371202
http://dx.doi.org/10.1161/JAHA.118.009557
work_keys_str_mv AT wittejeannine renalsolubleguanylatecyclaseisdownregulatedinsunitinibinducedhypertension
AT muhlbauermelanie renalsolubleguanylatecyclaseisdownregulatedinsunitinibinducedhypertension
AT braundiana renalsolubleguanylatecyclaseisdownregulatedinsunitinibinducedhypertension
AT steinbachantje renalsolubleguanylatecyclaseisdownregulatedinsunitinibinducedhypertension
AT golchertjanine renalsolubleguanylatecyclaseisdownregulatedinsunitinibinducedhypertension
AT rettigrainer renalsolubleguanylatecyclaseisdownregulatedinsunitinibinducedhypertension
AT griskolaf renalsolubleguanylatecyclaseisdownregulatedinsunitinibinducedhypertension